LSTM Home > LSTM Research > LSTM Online Archive

Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial

Liu, Chang, Guo, Changwei, Li, Fengli, Yu, Nizhen, Huang, Jiacheng, Peng, Zhouzhou, Kong, Weilin, Song, Jiaxing, Liu, Xiang, Fan, Shitao, Yue, Chengsong, Chen, Boyu, Zheng, Chong, Yuan, Xingyun, Sheng, Jian, Wu, Youlin, Sun, Bo, Zhao, Zengqiang, Zhu, Minzhen, Han, Ling, Shi, Qiang, Xia, Zhongbin, Shang, Xianjin, Li, Fengguang, Li, Rongzong, Yue, Feixue, Jiang, Shunfu, Song, Dengwen, Song, Min, Shan, Yuanjun, Ding, Chawen, Yao, Li, Yang, Yong, Chen, Junbin, He, Wencheng, Pan, Feibao, Zhang, Wensheng, Cai, Tieying, Han, Shibo, Li, Wei, Li, Gongbo, Gong, Chen, Huang, Liping, Huang, Cheng, Wang, Duolao ORCID: https://orcid.org/0000-0003-2788-2464, Kaesmacher, Johannes, Nguyen, Thanh N., Nogueira, Raul G., Saver, Jeffrey L., Zi, Wenjie, Chen, Yangmei, Yang, Qingwu, Qiu, Tao, Huang, Yihong, Zheng, Dai, Peng, Zhongyong, Tang, Sizhi, Li, Chuang, Li, Rongtong, Guo, Yongtao, Shen, Chaoxiong, Zhu, Xiurong, Wang, Yugang, Zhang, Lei, Guan, Haitao, Xu, Tao, Yang, Jie, Li, Linyu, Yang, Dahong, Ma, Jinfu, Xu, Xu, Shi, Xiaolei, Yang, Shihai, Sun, Wenzhe, Wang, Zhixi, Jiang, Shuyu and Wang, Zhiyuan (2025) 'Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial'. JAMA, Vol 333, Issue 7, pp. 589-598.

[img]
Preview
Text
JAMA24-8470R_Merged_PDF (1).pdf - Accepted Version

Download (681kB) | Preview

Abstract

Importance. Persisting or new thrombi in the distal arteries and the microcirculation have been reported to limit the benefits of successful endovascular thrombectomy for patients with acute ischemic stroke. It remains uncertain whether intra-arterial thrombolysis by urokinase following near-complete to complete reperfusion by thrombectomy improves outcomes among patients with ischemic stroke due to large vessel occlusion.

Objective. To assess the efficacy and adverse events of intra-arterial urokinase after near-complete to complete reperfusion by thrombectomy for acute ischemic stroke due to large vessel occlusion.

Design, Setting, and Participants. This investigator-initiated, randomized, open-label, blinded–end point trial was implemented at 35 hospitals in China, enrolling 535 patients with proximal intracranial large vessel occlusion presenting within 24 hours of time last known well, who achieved near-complete or complete reperfusion by endovascular thrombectomy and did not receive intravenous thrombolysis prior to the procedure. Recruitment took place between November 15, 2022, and March 29, 2024, with final follow-up on July 4, 2024.

Interventions. Eligible patients were randomly assigned to the intra-arterial urokinase group (a single dose of intra-arterial 100 000 IU urokinase injected in the initial target territory; n = 267) or control group (without intra-arterial thrombolysis; n = 267).

Main Outcomes and Measures. The primary efficacy outcome was the percentage of patients achieving survival without disability (modified Rankin Scale score of 0 or 1) at 90 days. The primary safety outcomes were mortality at 90 days and incidence of symptomatic intracranial hemorrhage within 48 hours.

Results. A total of 535 patients were enrolled (median age, 69 years; 223 [41.8%] female) and 532 (99.6%) completed the trial. The percentage of patients with survival without disability at 90 days was 45.1% (120/266) in the intra-arterial urokinase group and 40.2% (107/266) in the control group (adjusted risk ratio, 1.13 [95% CI, 0.94-1.36]; P = .19). Mortality at 90 days (18.4% vs 17.3%, respectively; adjusted hazard ratio, 1.06 [95% CI, 0.71-1.59]; P = .77) and incidence of symptomatic intracranial hemorrhage (4.1% vs 4.1%, respectively; adjusted risk ratio, 1.05 [95% CI, 0.45-2.44]; P = .91) were not significantly different between groups.

Conclusions and Relevance. Among patients with acute ischemic stroke due to large vessel occlusion, adjunct intra-arterial urokinase after near-complete to complete reperfusion by endovascular thrombectomy did not significantly increase the likelihood of survival without disability at 90 days.

Item Type: Article
Subjects: QV Pharmacology > Hematologic Agents > QV 190 Drugs affecting blood coagulation
WB Practice of Medicine > WB 26 Equipment and supplies
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.1001/jama.2024.23480
SWORD Depositor: JISC Pubrouter
Depositing User: JISC Pubrouter
Date Deposited: 19 Feb 2025 10:03
Last Modified: 20 Feb 2025 12:46
URI: https://archive.lstmed.ac.uk/id/eprint/26047

Statistics

View details

Actions (login required)

Edit Item Edit Item